Can Venclexta be used for Multiple Myeloma?
Although Venclexta is not FDA approved for use in Multiple Myeloma (MM), some research indicates that it may be promising for some MM patients who have failed at least one prior treatment, especially those with the genetic abnormality t(11;14) or with high levels of BCL-2. However, its use is not without controversy.
One major trial investigating the use of Venclexta for relapsed and refractory MM was halted early by the FDA due to safety concerns. The BELLINI clinical trial used a regimen of Venclexta plus bortezomib (a protease inhibitor) plus dexamethasone for 291 patients with MM. Unfortunately, interim results at an average of 17.9 months revealed 41/194 people (21.1%) assigned to the Venclexta combination regimen had died compared to only 11/97 (11.3%) of those assigned to placebo. This equated to an increase of approximately two-fold in the relative risk of death from Venclexta. The FDA halted the trial on March 6, 2019; however, patients who were experiencing a clinical benefit could elect to continue if they wanted to. The FDA also suspended enrolment in other MM trials involving Venclexta that were ongoing at the time.
However, when researchers performed a subgroup analysis of the MM patients who experienced a clinical benefit, they found two subgroups of patients, those with the t(11;14) translocation and those with high levels of BCL-2, lived significantly longer without disease progression and there was also a non-significant trend towards longer survival.
Translocation is a genetic alteration that is common in MM patients. During translocations, chromosome segments and their genes change positions within the same chromosome or into another chromosome. The t(11;14) translocation means there is a translocation between chromosome 11 and chromosome 14.
Subgroup analysis of people with the t(11;14) translocation or high levels of BCL-2 revealed that 74% had a reduction in their risk of disease progression or death compared to placebo, higher response rates (88% vs. 70%), higher rates of complete response or better (42% vs. 3%), and higher rates of minimal residual disease negativity (19% vs. 0%), as well as a trend toward longer survival.
These findings do support the use of Venclexta in combination with other treatments for relapsed or refractory multiple myeloma bearing the t(11;14) translocation or with high levels of BCL-2. Other trials are currently ongoing.
Related questions
- Is Venclexta (venetoclax) chemotherapy?
- How effective is Venclexta?
- How long do you take Venclexta for?
References
- Venclexta-Darzalex Combos Show Strong Response Rates in Multiple Myeloma Trial, Early Data Show. Dec 4 2019. Myeloma Research News https://myelomaresearchnews.com/2019/12/04/venclexta-darzalex-combos-showing-strong-response-rates-in-advanced-multiple-myeloma-trial/
- Inacio P. Venclexta Safe and Effective for Certain Multiple Myeloma Patients, Trial Data Show. Dec 3, 2019. Multiple Myeloma News https://myelomaresearchnews.com/2019/12/03/venclexta-safe-effective-in-subset-relapsed-refractory-myeloma-patients-data-show/#:~:text=Venclexta%20(venetoclax)%2C%20approved%20to,data%20from%20two%20studies%20suggest.
- FDA Warns about the risks associated with the investigational use of Venclexta in Multiple Myeloma [3/21/2019] U.S. Food and Drug Administration https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-risks-associated-investigational-use-venclexta-multiple-myeloma
Read next
How is Venclexta (venetoclax) used for AML?
Venclexta is given once-daily with food in combination with either azacytidine, decitabine, or low-dose cytarabine in adults with AML. It works by binding to a specific protein that is over-expressed in cancerous lymphocytes, killing them. Continue reading
How does Venclexta work?
Venclexta's mechanism of action involves binding directly to a protein called BCL-2, which is overexpressed on some cancer cells. When Venclexta binds to BCL-2, it displaces other proteins, which help activate apoptosis -- or programmed cell death. Continue reading
What are the best treatments for Multiple Myeloma?
Multiple myeloma is a cancer of plasma cells, which are white blood cells responsible for producing antibodies. While not yet curable, advancements in therapy have transformed it into a manageable condition with treatments that can achieve long-term disease control and improved quality of life. Initial treatment usually involves multi-drug combinations, such as bortezomib (a proteasome inhibitor), lenalidomide (an immunomodulatory drug), and dexamethasone (a steroid).
Continue readingSee also:
Aimovig
Learn about Aimovig (erenumab-aooe) a once-monthly, injectable medication that can be ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Nurtec ODT
Nurtec ODT (rimegepant) is used to treat acute migraines and prevent episodic migraines, by ...
Emgality
Emgality (galcanezumab-gnlm) is a CGRP antagonist for the preventive treatment of migraine and for ...
Inderal
Inderal (propranolol) is used to treat angina, high blood pressure and heart rhythm disorders ...
Ajovy
Ajovy (fremanezumab-vfrm) is a preventive migraine treatment. Includes Ajovy side effects ...
Vyepti
Vyepti (eptinezumab-jjmr) is used for the preventive treatment of migraine. Includes Vyepti ...
Botox Cosmetic
Botox Cosmetic is a prescription treatment for fine lines and wrinkles. It temporarily improves the ...
Fremanezumab
Fremanezumab is used for chronic migraine, headache, migraine, migraine prevention
Related medical questions
- How Does Chemotherapy Work for Multiple Myeloma?
- Is Velcade a type of chemotherapy?
- Can Darzalex cure Multiple Myeloma?
- Is Kyprolis a chemo drug and how does it work?
- How long does Velcade stay in your body?
- How effective is Velcade for multiple myeloma?
- Is Darzalex chemotherapy?
- What’s the difference between Tecvayli and Talvey?
- What is the mechanism of action for Tecvayli (teclistamab-cqyv)?
- Is Tecvayli FDA approved as a multiple myeloma treatment?
- Where can I find the Tecvayli FDA package insert?
- How is Kyprolis (carfilzomib) administered?
- What is the success rate for Carvykti for Multiple Myeloma?
- What is the success rate of Tecvayli?
- What should I know about the Tecvayli REMS program?
- What is Empliciti (elotuzumab)? and how does Empliciti work?
- What’s the mechanism of action of Carvykti?
- Is Abecma an orphan drug?
- What is Ninlaro used for?
Drug information
Related support groups
- Venclexta (6 questions, 4 members)
- Venetoclax (6 questions, 7 members)
- Multiple Myeloma (24 questions, 54 members)